for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

160.03USD

Change

-2.73(-1.68%)

Volume

807,833

Today's Range

158.66

 - 

162.40

52 Week Range

109.17

 - 

173.62

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
162.76
Open
162.00
Volume
807,833
3M AVG Volume
161.90
Today's High
162.40
Today's Low
158.66
52 Week High
173.62
52 Week Low
109.17
Shares Out (MIL)
2,628.68
Market Cap (MIL)
427,397.10
Forward P/E
16.90
Dividend (Yield %)
2.48

Next Event

Johnson & Johnson at Raymond James Institutional Investors Conference (Virtual)

Latest Developments

More

Novavax Expects To Start Pediatric Studies For Its Covid-19 Vaccine In Spring

Johnson & Johnson Announces Submission To World Health Organization For Emergency Use Listing Of Investigational Single-Shot Janssen COVID-19 Vaccine Candidate

EMA Receives Application For Conditional Marketing Authorisation Of COVID-19 Vaccine Janssen

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

NEW BRUNSWICK, NJ

08933-0001

United States

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

1.94 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

81.6K

2019

82.1K

2020

82.6K

2021(E)

91.5K
EPS (USD)

2018

8.180

2019

8.680

2020

8.030

2021(E)

9.496
Price To Earnings (TTM)
30.11
Price To Sales (TTM)
5.18
Price To Book (MRQ)
6.76
Price To Cash Flow (TTM)
19.75
Total Debt To Equity (MRQ)
55.73
LT Debt To Equity (MRQ)
51.57
Return on Investment (TTM)
11.34
Return on Equity (TTM)
8.67

Latest News

Latest News

FDA advisory panel to review Johnson & Johnson COVID-19 vaccine with thumbs up expected

A panel of expert advisers to the U.S. Food and Drug Administration began a meeting to discuss Johnson & Johnson's one-dose COVID-19 vaccine on Friday, setting the stage for a possible emergency use authorization as early as this week.

J&J COVID-19 vaccine set to get EU nod in early March - Bloomberg News

The European Union's medicines regulator is expected to recommend drugmaker Johnson & Johnson's COVID-19 vaccine on March 11, Bloomberg News reported https://bloom.bg/3stLMZR on Friday, a move that could give the region its fourth coronavirus vaccine.

FDA advisory panel to review Johnson & Johnson COVID-19 vaccine with thumbs up expected

A panel of expert advisers to the U.S. Food and Drug Administration is expected to recommend authorization of a one-dose COVID-19 vaccine from Johnson & Johnson on Friday, setting the stage for the unleashing of millions more doses across the country next week.

BRIEF-EMA Is Expected To Give J&J COVID-19 Shot Nod On March 11 - Bloomberg News

* J&J SHOT SET TO GET EU NOD IN EARLY MARCH, EASING SUPPLY SQUEEZE - BLOOMBERG NEWS

Bahrain first to approve Johnson & Johnson COVID-19 vaccine for emergency use - regulator

Bahrain has approved Johnson & Johnson's one-dose COVID-19 vaccine for emergency use, the first country to do so, the National Health Regulatory Authority (NHRA) said on Thursday.

Bahrain first to approve Johnson & Johnson COVID-19 vaccine for emergency use: regulator

Bahrain has approved Johnson & Johnson's one-dose COVID-19 vaccine for emergency use, the first country to do so, the National Health Regulatory Authority (NHRA) said on Thursday.

White House to roll out Johnson & Johnson vaccine doses next week, pending authorization

The United States expects to roll out three to four million doses of Johnson & Johnson's COVID-19 vaccine next week, pending authorization from the Food and Drug Administration, White House COVID-19 response coordinator Jeff Zients said on Wednesday.

Johnson & Johnson's one-dose vaccine closes in on U.S. approval

Johnson & Johnson's one-dose COVID-19 vaccine appeared safe and effective in trials, the U.S. Food and Drug Administration said Wednesday, paving the way for its approval for emergency use as soon as this week.

White House sees 3-4 mln J&J COVID-19 vaccine doses allocated next week

The United States expects to allocate three to four million doses of Johnson & Johnson's COVID-19 vaccine next week, pending approval later this week, the White House's COVID-19 response coordinator, Jeffrey Zients, said on Wednesday.

BRIEF-Johnson & Johnson's COVID-19 vaccine effective, safe - FDA staff's briefing docs

* U.S. FDA STAFF PUBLISHES BRIEFING DOCUMENTS ON JOHNSON & JOHNSON COVID-19 VACCINE AHEAD OF ADVISORY COMMITTEE MEETING ON FRIDAY

Johnson & Johnson's one-shot COVID-19 vaccine effective and safe- FDA staff

Johnson & Johnson's one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.

Johnson & Johnson ready to ship nearly 4 million doses of COVID-19 vaccine in U.S.

Johnson & Johnson expects to be able to ship nearly 4 million doses of its COVID-19 vaccine upon authorization in the U.S., an executive said at a hearing in the U.S. House of Representatives on Tuesday.

South Africa says J&J, Pfizer, Moderna vaccines those for 'immediate use'

South Africa's health minister said on Tuesday that government advisers had organised COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson (J&J), Pfizer and Moderna shots.

South Africa says J&J, Pfizer, Moderna vaccines in group for "immediate use"

South Africa's health minister said on Tuesday that a committee advising the government had grouped COVID-19 vaccines into three groups and those considered for "immediate use" were the Johnson & Johnson, Pfizer and Moderna shots.

Johnson & Johnson sets aside almost $4 billion for talc verdict, filing shows

Drugmaker Johnson & Johnson set aside $3.9 billion in litigation expenses in 2020, which it said was "primarily associated with talc-related reserves and certain settlements".

France's Sanofi to help Johnson & Johnson manufacture COVID-19 vaccine

French healthcare company Sanofi will provide COVID-19 vaccine manufacturing support to U.S. peer Johnson & Johnson, Sanofi said on Monday.

Johnson & Johnson applies to WHO for emergency use listing of COVID-19 vaccine

Johnson & Johnson said on Friday it had submitted data to the World Health Organization (WHO) for emergency use listing of its COVID-19 vaccine, which would allow for wider access of the one-dose shot.

Johnson & Johnson submits emergency use listing to WHO for COVID-19 vaccine

Johnson & Johnson said on Friday it had submitted for emergency use listing of its COVID-19 vaccine to the World Health Organization.

Pfizer study another worry for South Africa's vaccine rollout

Scientists will meet on Thursday to advise South Africa's government on its next steps after a study suggested the dominant local coronavirus variant may reduce protective antibodies from Pfizer's COVID-19 vaccine by two-thirds.

Johnson & Johnson has only a few million COVID-19 vaccine doses in stock as likely launch nears

Johnson & Johnson has only a few million doses of its experimental COVID-19 vaccine in its inventory even as likely U.S. regulatory authorization is only a few weeks away, White House officials said on Wednesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up